On-line documentation of diagnostic and interventional procedures and automated assessment of CAD prevention recommendations

Computers in Cardiology

Volumn , Issue , 1999, Pages 383-386

  Simon, Bernd C ^a   Schaefer, J ^a   Gruenfeld, M ^b   Ehlers, M ^a   Maisch, B ^a  

^a UNIVERSITY HOSPITAL MARBURG   (Germany)

^b MSP GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOCARDIOGRAPHY; COMPUTER AIDED DIAGNOSIS; COMPUTER SOFTWARE; DATABASE SYSTEMS; RISK ASSESSMENT;

CARDIAC INTERVENTIONS; SOFTWARE PACKAGE CARDDAS;

CARDIOLOGY;

EID: 0033282879     PISSN: 02766574     EISSN: None     Source Type: Conference Proceeding    
DOI: None     Document Type: Conference Paper

References (9)

1. Brennecke R, Kadel C. Requirements for quality assessment in coronary angiography and angioplasty. European Heart Journal 1995;16:1578-1588.
2. Winding O, Clamp S, Ohmann C. Quality and its evaluation. Techn Health Care 1993;1:101-5.
3. West of Scotland Coronary Prevention Study Group: Influence of Pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study. Circulation 1998;97:1440.
4. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto AMJ: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS / TexCAPS. Air Force / Texas Coronary Atherosclerosis Prevention Study. JAMA 1998;279:1615.
5. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ: Prevention of Coronary Heart Disease With Pravastatin in Men With Hypercholesterolemia. N Engl J Med 1995;333:1301, (Abstract).
6. Scandinavian Simvastatin Survival Study Group: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383.
7. Szucs TD, Guggenberger G, Berger K, Maerz W, Schaefer JR: Pharmakoökonomische Bewertung von Pravastatin in der Sekundärprävention der koronaren Herzkrankheit bei Patienten mit durchschnittlichen Cholesterinwerten. Eine Analyse für Deutschland auf der Grundlage der CARE-Studie Herz 1998,23:319
8. The Long-Term Intervention With Pravastatin In Ischaemic Disease (LIPID) Study Group: Prevention of cardiovascular events and death with Pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349.
9. Schaefer JR, Herzum M, Maisch B: Prävention der koronaren Herzerkrankung - "evidence based medicine" in der Lipidsenkertherapie. Herz 1999;3.